COMPANY:

Castle Biosci

''Castle Biosciences, Inc...today announced new data demonstrating the clinical value of its DecisionDx-Melanoma test in improving sentinel lymph node (SLN) biopsy (SLNB) decision making and enhancing recurrence risk prediction in patients with cutaneous melanoma (CM). ''

"Natera...today announced another successful readout for its ECD program, which is evaluating a blood-based screening test for the detection of CRC and advanced adenomas (AA). This latest analysis from the U.S. based, prospective PROCEED-CRC clinical trial (NCT06620627) focused on the detection of AAs, which are precancerous polyps with specific features that indicate a higher risk of progression to colorectal cancer. Detecting these lesions early is a critical step in preventing cancer before it develops."

"Castle Biosciences...today announced new data demonstrating that its TissueCypher® Barrett’s Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The research will be presented in three posters at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting, taking place Oct. 27–29, 2025, in Phoenix, Arizona, including one selected for a Presidential Poster Award."

"Castle Biosciences...today announced that it is presenting data on its DecisionDx®-Melanoma test and its pipeline atopic dermatitis (AD) gene expression profile (GEP) test at the 25th Annual Fall Clinical Dermatology Conference®, taking place Oct. 23–26, 2025, in Las Vegas, Nevada."

"Castle Biosciences, Inc...today announced that new data demonstrating the personalized risk stratification provided by its TissueCypher Barrett’s Esophagus test will be shared via a podium presentation at the American Foregut Society's (AFS) 2025 Annual Meeting, taking place Sept. 11-13, 2025, in Dallas."

"Castle Biosciences, Inc...today announced the publication of two new studies related to its DecisionDx-SCC test, adding to its validated uses for patients with high-risk cutaneous squamous cell carcinoma (SCC).1,2 DecisionDx-SCC is a gene expression profile test (40-GEP) designed to use a patient’s tumor biology to predict individual risk of metastasis as well as response to adjuvant radiation therapy (ART).:"

"Castle Biosciences, Inc...today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time."

"Castle Biosciences, Inc...today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). DecisionDx-Melanoma is a gene expression profile (GEP) test that provides comprehensive, personalized results to guide risk-aligned management decisions for patients diagnosed with stage I-III cutaneous melanoma."

"Castle Biosciences, Inc...will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30-June 3, 2025, in Chicago. This includes the latest findings from Castle's ongoing collaboration with the National Cancer Institute's Surveillance, Epidemiology and End Results (NCI's SEER) Program Registries affirming the significant, independent risk stratification provided by DecisionDx-Melanoma in an expanded, real-world cohort of more than 13,500 patients who received the test as part of their melanoma care."

"Castle Biosciences...today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time."

"Castle Biosciences, Inc...announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed....The transaction is expected to close in the coming weeks, subject to the customary closing conditions."

"Castle Biosciences, Inc...today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma."